Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast

[News]

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

More... (https://www.news-medical.net/news/20181022/Pfizer-announces-PALOMA-3-trial-results-in-patients-with-HR2b-HER2-metastatic-breast-cancer.aspx)